Hyperthyroid atrial fibrillation: Does it matter for stroke risk?

Cardiology (Switzerland)

Volumn 128, Issue 1, 2014, Pages 51-53

  Poulin, Marie France ^a   Doukky, Rami ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Jr Hospital of Cook County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANTICOAGULANT AGENT; D DIMER; FIBRINOGEN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLOOD CLOTTING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DISEASE SEVERITY; EXTERNAL VALIDITY; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROID ATRIAL FIBRILLATION; HYPERTHYROIDISM; INTERNAL VALIDITY; NOTE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RISK FACTOR; SINUS RHYTHM; EUTHYROIDISM; COMPLICATION; FEMALE; MALE; THROMBOEMBOLISM; THROMBOPHILIA;

ATRIAL FIBRILLATION; FEMALE; HUMANS; HYPERTHYROIDISM; MALE; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 84893678415     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000357613     Document Type: Note

References (15)

1. Chen Q, Yan Y, Zhang L, Cheng K, Liu Y, Zhu W: Effect of hyperthyroidism on the hypercoagulable state and thromboembolic events in patients with atrial fibrillation. Cardiology 2014;127:176-182.
2. Wann LS, Curtis AB, January CT, et al: 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57: 223-242.
3. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ: Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133: 546S-592S.
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001; 285: 2864-2870.
5. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-272.
6. Petersen P, Hansen JM: Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988; 19: 15-18.
7. Siu CW, Pong V, Zhang XH, Chan YH, Jim MH, Liu SS, Yiu KH, Kung AWC, Lau CP, Tse HF: Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism. Heart Rhythm 2009; 6: 169-173.
8. Bar-Sela S, Ehrenfeld M, Eliakim M: Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981; 141: 1191-1192.
9. Staffurth JS, Gibberd MC, Fui SN: Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J 1977; 2: 688-690.
10. Hurley DM, Hunter AN, Hewett MJ, Stockigt JR: Atrial fibrillation and arterial embolism in hyperthyroidism. Aust NZ J Med 1981; 11: 391-393.
11. Yuen RW, Gutteridge DH, Thompson PL, Robinson JS: Embolism in thyrotoxic atrial fibrillation. Med J Aust 1979; 1: 630-631.
12. Sheu JJ, Kang JH, Lin HC: Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke 2010; 41: 961-966.
13. Friberg L, Rosenqvist M, Lip GY: Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 1500-1510.
14. Franchini M, Montagnana M, Manzato F, Vescovi PP: Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost 2009; 35: 288-294.
15. Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee JD, Shimizu A, Hayano M, Yano K: D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006; 109: 59-65.